The Latest
-
Trump names RFK Jr. as his pick to lead HHS
If confirmed to the role, Robert F. Kennedy Jr. would oversee the country's top health agencies, including the Food and Drug Administration and the Centers for Disease Control and Prevention.
Updated Nov. 14, 2024 -
Profile
Left to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past
While Martin Shkreli smirked his way through a public securities fraud investigation, Ron Tilles became interim CEO of Turing Pharmaceuticals, ready or not. Here’s his story.
-
From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies
As the industry’s marketing dollars shift, companies are targeting potential patients in unique ways.
-
Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’
As Big Pharma embraces telehealth to sell medicines directly to patients, lawmakers wonder whether the programs skirt anti-kickback rules.
-
Pharma’s grip on cancer R&D is having unintended consequences
A pair of studies paint a complicated picture of funding and missed research opportunities.
-
What RFK Jr.’s influence could mean for pharma
Past comments hint at the changes Robert F. Kennedy Jr. could make across the various sectors of healthcare.
-
Spravato is just the beginning in a new wave of depression meds
Psychiatry is getting more targeted as drugmakers develop a new range of treatments for depression.
-
With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC
Speculation around pharma dealmaking and the next FDA commissioner has begun.
-
Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in
Dealmaking this year has been largely muted, but M&A trends are pointing to the areas where pharma is placing the most emphasis.
-
An RNAi renaissance is creating a new generation of startups
Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.
-
A diabetes drug, twice rejected, stumbles again — but its developer persists
After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 diabetes therapy.
-
Profile
CEO with type 1 diabetes works to deliver ‘world’s first’ functional cure
Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.
-
Two former Alexion leaders fight through a tough market to maintain a rare disease biotech
Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey difficult.
-
Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s
Pfizer’s second-to-market goals for its oral GLP-1 drugs underscore big opportunities in the space.
-
Pharma takes aim at a wily foe — the Epstein-Barr virus
The pernicious and widespread virus has been linked to a range of diseases including MS and long COVID.
-
A sickle cell cure exists. But patients need more than just gene therapy.
Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier.
-
PharmaVoice 100
2024 PharmaVoice 100s: Cancer Care Visionaries
Leaders who envision a world without cancer through oncology innovation.
-
Big Pharma earnings hang hope on the next generation of blockbusters
Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.
-
PharmaVoice 100
2024 PharmaVoice 100s: Clinical Trial Pros
Experts raising the bar in clinical trial design and collaboration.
-
Backlash builds against Novo’s Catalent takeover
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.
-
PharmaVoice 100
2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers
Leaders molding the cutting-edge cell and gene therapy field into tomorrow's cures.
-
Deep Dive // PharmaVoice 100
The 2024 PharmaVoice 100
This year’s PharmaVoice 100 encompasses the industry’s ongoing revolutions and leaders who are not only navigating these changes, but at times, forging new paths for others to follow.
-
Q&A
How AZ’s respiratory wins are ramping up for a bigger prize in COPD
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
-
PharmaVoice 100
2024 PharmaVoice 100s: Rare Disease Warriors
Pharma pros driving drug development and access for patients with high unmet needs.
-
Where Big Pharma’s campaign cash is flowing in this election
Big Pharma CEOs are hedging all bets by supporting both sides of the aisle in the 2024 election.